Zodiac-themed e-cigarette launches in U.S. as Geek Bar unveils new Meloso Bar 30000

Oct.29.2024
Zodiac-themed e-cigarette launches in U.S. as Geek Bar unveils new Meloso Bar 30000
Geek Bar is launching the Zodiac-themed disposable e-cigarette 'Meloso Bar 30000' in the U.S., featuring a 3D curved screen and approximately 30,000 puffs. Currently, the Meloso Bar 30000 is not yet listed on the official Geek Bar website, but is available on several U.S. distributor sites.

Recently, 2Firsts noticed that the Geek Bar brand has launched the Geek Bar Meloso Bar 30000 disposable e-cigarette on popular American retailers' websites such as vapesourcing. The product features a constellation-themed design and 30000 puffs of high-draw mouthpieces.

 

Zodiac-themed e-cigarette launches in U.S. as Geek Bar unveils new Meloso Bar 30000
Image source: vapesourcing website

 

The main features of the Geek Bar Meloso Bar 30000 include:

 

  • Nicotine Concentration: 5% (50mg)
  • Puff Count: Approximately 30,000 puffs in standard mode / 15,000 puffs in pulse mode
  • E-liquid Capacity: Pre-filled with 18ml
  • Charging: Supports USB Type-C charging
  • Screen Functionality: 5.68-inch 3D curved screen displaying battery and e-liquid levels, along with 12 zodiac signs
  • Flavor Options: 12 flavors, including Mexican Mango, Strawberry Banana Ice, etc.
  • Price Range: Approximately $12.99 - $14.99

 

In terms of design, the Geek Bar Meloso Bar 30000 incorporates the popular 3D curved screen seen in the U.S. market. The 12 different zodiac indicators not only display unique visual cues but also correspond to specific flavors. For example, Capricorn is associated with Mexican Mango, while Leo offers Summer Grape.

 

Zodiac-themed e-cigarette launches in U.S. as Geek Bar unveils new Meloso Bar 30000
Image source: vapesourcing website

 

The Geek Bar Meloso Bar 30000 is now available on several U.S. e-cigarette distributor websites, including Vapesourcing and Vape123, and has received positive feedback from consumers.

 

In reviews, users highlighted that the product offers: “Amazing flavor”. “The flavor options are rich and bold, offering a satisfying hit each time.”

 

Zodiac-themed e-cigarette launches in U.S. as Geek Bar unveils new Meloso Bar 30000
User product evaluations posted on the dealer's website | Image source: vapesourcing

 

Zodiac-themed e-cigarette launches in U.S. as Geek Bar unveils new Meloso Bar 30000
User product reviews posted on the dealer's website | Image source: vape123

 

Notably, similar to the recently launched Geek Bar Digi Flavor BRK magnetic e-cigarette series - released in the U.S. by Geek Bar and its sister brand Digiflavor - the Geek Bar Meloso Bar 30000 has also not yet appeared on Geek Bar's official website.

 

2Firsts will continue to monitor the latest e-cigarette products and market trends in the U.S., providing the public with accurate and authoritative industry insight.

 


 

2Firsts' product column remains committed to delivering readers the latest product updates in the new tobacco field. We invite readers to submit insights and news on e-cigarette developments.

 

For unique perspectives or information, feel free to contact us at carrie.cai@2firsts.com or scan the QR code below.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

JAMA Issues First U.S. Clinical Guidance on Vaping for Smoking Cessation, Urging Complete Switch From Cigarettes
JAMA Issues First U.S. Clinical Guidance on Vaping for Smoking Cessation, Urging Complete Switch From Cigarettes
JAMA has published a Special Communication offering systematic recommendations for U.S.-based clinicians on the use of nicotine e-cigarettes in adult smoking cessation. Developed by the Harm Reduction Workgroup of the Society for Research on Nicotine and Tobacco’s Treatment Research Network, the paper recommends including e-cigarettes alongside FDA-approved cessation medications in risk-benefit discussions. It cites high-certainty evidence that nicotine e-cigarettes achieve higher quit rates than nicotine replacement therapy and evidence suggesting efficacy comparable to highly effective medications such as varenicline and cytisine. For adults who choose vaping to quit, the authors recommend FDA-authorized products, sufficient nicotine delivery and a rapid, complete transition away from cigarettes rather than prolonged dual use.
Aug.13
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
IQOS Enters Kantar BrandZ Global Top 100 for First Time, Valued at $36.6 Billion and Ranked No. 74
IQOS Enters Kantar BrandZ Global Top 100 for First Time, Valued at $36.6 Billion and Ranked No. 74
Philip Morris International’s IQOS has entered the Kantar BrandZ Top 100 Most Valuable Global Brands for the first time, ranking No. 74 with a brand value of $36.634 billion and becoming one of only three newcomers to the 2026 ranking. Kantar said the combined value of the Global Top 100 reached $13.1 trillion, up 22% year on year, while the threshold for entry rose to a record high. PMI says IQOS has more than 35 million users worldwide and surpassed $10 billion in annual net revenues within a decade of launch.
Sep.03
UK Vape Maker Riot Enters Clacton By-Election to Fight Government 'White Packaging' Proposals
UK Vape Maker Riot Enters Clacton By-Election to Fight Government 'White Packaging' Proposals
British e-liquid manufacturer Riot Labs has introduced a fictional “candidate” called Riot Man around the Clacton parliamentary by-election, seeking to mobilize consumers and retailers against parts of the UK government’s proposed restrictions on vape packaging, device appearance and retail displays. Riot Man is not listed as an official candidate.
Aug.12
EU ‘TPD3’ Enters Next Phase on Aug. 14 as Fragmented Vape and Nicotine Pouch Rules Push the Single Market Toward Regulatory Overhaul
EU ‘TPD3’ Enters Next Phase on Aug. 14 as Fragmented Vape and Nicotine Pouch Rules Push the Single Market Toward Regulatory Overhaul
A 12-week European Commission consultation on revising the Tobacco Products Directive and Tobacco Advertising Directive is due to close on Aug. 14, 2026. The Commission has identified e-cigarette flavours, disposable vapes, tobacco heating devices, nicotine pouches, nicotine-free e-cigarettes, packaging and digital marketing among areas for possible new EU rules. National regulations already vary significantly across the bloc, a fragmentation the Commission says creates internal-market barriers and distorts competition. No formal revised TPD/TAD legislative text has yet been published, with the Commission currently indicating December 2026 for the legislative initiative.
Aug.14
Australia Adds 6-Methylnicotine to Schedule 9 Prohibited Substances, Effective October 1
Australia Adds 6-Methylnicotine to Schedule 9 Prohibited Substances, Effective October 1
Australia's Therapeutic Goods Administration published a final decision on September 25 to classify 6-methylnicotine as a Schedule 9 prohibited substance under the Poisons Standard, effective October 1, 2026. TGA said the chemical has been reported in e-cigarette liquids sold in Australia and marketed as nicotine-free or nicotine alternatives, while evidence also indicates its use in preparations such as oral pouches. The government originally proposed a Schedule 7 classification but ultimately adopted the stricter Schedule 9 designation, citing acute toxicity, dependence risk, use in unapproved consumer products and misleading marketing.
News
Sep.29 by 2Firsts Perspectives